

April 18, 2025

Dear Nuclear Medicine Program Director:

In March 2023, the ABNM sent a letter (via email) to Nuclear Medicine Program Directors regarding the extension of the ABNM provisional criteria requirements for radionuclide therapy.

As stated in the original letter in November 2020, the ABNM has decided to extend the provisional requirements until the ACGME gives formal notice regarding the RRC guidelines. The ABNM will continue to accept the ACGME Nuclear Medicine program requirements or the ABNM provisional requirements for the future initial certification exam applicants until further notice from the ACGME. The requirements are outlined below:


ABNM Requirements Radionuclide Therapy		
	ACGME Current Criteria (effective since 2014)	ABNM Provisional Criteria (optional since 2021)
I-131 ≤ 33 mCi (benign)	10 - 15	5+
I-131 > 33 mCi (malignant)	10 - 15	5+
Parental	5	*10+
Total Therapies	35	35
<b>*At least 2 different FDA approved radiopharmaceuticals excluding <sup>96</sup>Y microspheres</b>		


The ABNM will require all candidates using the ABNM provisional pathway to submit a [training record](#) that includes the date of treatment, radiopharmaceutical, and administered dose.

The ABNM believes the new criteria will improve resident training, give Nuclear Medicine Program Directors more flexibility in meeting ABNM requirements, and maintain high standards for the specialty. We will continue to re-evaluate requirements for radionuclide therapy.

As always, thank you for supporting Nuclear Medicine training at your institution, and training young professionals to be the future leaders of our specialty. You may send your question or comments to [abnm@abnm.org](mailto:abnm@abnm.org).

Sincerely,

  
Liza Lindenberg, MD  
Chair

  
Kirk Frey, MD, PhD  
Executive Director

LL/KF/mw/mf

Chair  
Liza Lindenberg, MD  
Bethesda, Maryland

Vice Chair  
Maria Rosana Ponisio, MD  
Saint Louis, Missouri

Secretary Treasurer  
Lisa Bodei, MD, PhD  
New York, New York

Past Chair  
Ryan D. Niederkohr, MD  
Santa Clara, California

#### Directors

Twyla Bartel, DO, MBA  
Tulsa, Oklahoma

Benjamin L. Franc, MD, MS, MBA  
Stanford, California

K. Elizabeth Hawk, MS, MD, PhD  
Studio City, California

Hossein Jadvar, MD, PhD, MPH, MBA, MSL  
Los Angeles, California

Hollie Anne Lai, MD  
Orange, CA

Yusuf Menda, MD  
Iowa City, Iowa

Medhat M. Osman, MD, ScM, PhD  
Saint Louis, Missouri

Katherine A. Zukotynski, MD  
Hamilton, Ontario

Executive Director  
Kirk A. Frey, MD, PhD  
Ann Arbor, Michigan

Associate Executive Director  
Joanna R. Fair, MD, PhD  
Albuquerque, NM

Administrator  
Maria J. Watts, MBA  
Saint Louis, Missouri